Post by icemandios on Mar 28, 2016 18:33:34 GMT
Aug 13, 2015 Michael Bond
On Wednesday, Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)’s shares inclined 10.34% to $2.24.
Actinium Pharmaceuticals Inc (ATNM) declared the closing of its formerly declared registered direct offering of $5.0 million of its common stock. Under the terms of the subscription agreements, the Company issued an aggregate of 1,923,078 shares of the Company’s common stock at a purchase price of $2.60 per share. This financing was led by investor Dr. Phillip Frost.
Actinium anticipates using the net proceeds for general corporate purposes, counting capital expenditures, the advancement of our product candidates in clinical trials, such as Iomab™-B and Actimab-A, preclinical trials, to support licensing activities, and to meet working capital needs.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products comprise Actimab-A, an antibody-drug construct, which comprises monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML).
Frost's investment, while an undisclosed amount, would not have created a 5% interest and, therefore, was not required to be filed with the SEC. The company is located in NY, NY. (grabbing at straws, here, there was the recent filing with the Sec of State in NY for Opko Pharmaceuticals, LLC but the pharmaceutical division of OPK has no physical plant in NY - so far).
Might ATNM be a target for acquisition? I don't know; I just know Frost invested and would have to buy more stock to be required to report it. And I know that Opko Pharmaceuticals LLC not so long ago registered with the Sec of State of NY, but they ain't there. Might be something........might be nothing.
ATNM Home Page
On Wednesday, Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)’s shares inclined 10.34% to $2.24.
Actinium Pharmaceuticals Inc (ATNM) declared the closing of its formerly declared registered direct offering of $5.0 million of its common stock. Under the terms of the subscription agreements, the Company issued an aggregate of 1,923,078 shares of the Company’s common stock at a purchase price of $2.60 per share. This financing was led by investor Dr. Phillip Frost.
Actinium anticipates using the net proceeds for general corporate purposes, counting capital expenditures, the advancement of our product candidates in clinical trials, such as Iomab™-B and Actimab-A, preclinical trials, to support licensing activities, and to meet working capital needs.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products comprise Actimab-A, an antibody-drug construct, which comprises monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML).
Frost's investment, while an undisclosed amount, would not have created a 5% interest and, therefore, was not required to be filed with the SEC. The company is located in NY, NY. (grabbing at straws, here, there was the recent filing with the Sec of State in NY for Opko Pharmaceuticals, LLC but the pharmaceutical division of OPK has no physical plant in NY - so far).
Might ATNM be a target for acquisition? I don't know; I just know Frost invested and would have to buy more stock to be required to report it. And I know that Opko Pharmaceuticals LLC not so long ago registered with the Sec of State of NY, but they ain't there. Might be something........might be nothing.
ATNM Home Page
